Current Report Filing (8-k)
26 January 2022 - 08:51AM
Edgar (US Regulatory)
false000163605000016360502022-01-192022-01-19
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
January 19, 2022
Sio Gene Therapies Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Delaware
|
|
001-37418
|
|
85-3863315
|
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
|
130 West 42nd Street
26th Floor
New York, New York 10036
(Address of principal executive offices) (Zip Code)
|
(Registrant’s telephone number, including area code):
+1 877 746 4891
N/A
(Former name, former address and former fiscal year, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligations of the registrant
under any of the following provisions:
|
|
|
|
|
|
|
|
|
|
☐
|
|
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
|
|
☐
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
|
|
☐
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
|
Securities Registered pursuant to Section 12(b) of the
Act:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Title of each Class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
|
Common Stock, par value $0.00001 per share
|
|
SIOX
|
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter):
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Item 5.02 Departure of Directors or Certain
Officers; Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers.
On January 19, 2022, the Compensation Committee of the Board of
Directors of Sio Gene Therapies Inc. (the "Registrant")
adopted a retention program for all of the Registrant's employees,
including its executive officers (the "Retention
Program").
Under the Retention Program, each employee employed on a full-time
basis as of January 19, 2022 will be eligible to receive a cash
retention bonus totaling 100% of such participant's current target
annual bonus for the fiscal year ending March 31, 2023, in addition
to such participant's regular target annual bonus for such fiscal
year. The retention bonus will be paid in three equal installments
on July 15, 2022, October 14, 2022 and January 13, 2023, subject to
each participant’s continued full-time employment through the
applicable payment date. The Retention Program does not modify the
existing terms of existing employment arrangements as well as the
Registrant’s annual cash bonus plan.
The foregoing summary of the material terms of the Retention
Program does not purport to be complete and is subject to, and
qualified in its entirety by reference to, a description of the
terms of the Retention Program approved by the Compensation
Committee of the Registrant’s Board of Directors. The Registrant
intends to file such a copy of the Retention Plan with its Annual
Report on Form 10-K for the fiscal year ending March 31,
2022.
SIGNATURE
Pursuant to the requirements of the
Securities Exchange Act of 1934, the Registrant has duly caused
this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
SIO GENE THERAPIES INC.
|
|
|
|
|
|
|
|
|
Dated:
|
January 25, 2022
|
|
|
|
|
|
|
|
By:
|
/s/ David Nassif
|
|
|
|
|
Name:
|
David Nassif
|
|
|
|
|
Title:
|
Chief Financial Officer and General Counsel
|
|
Axovant Gene Therapies (NASDAQ:AXGT)
Historical Stock Chart
From May 2022 to Jun 2022
Axovant Gene Therapies (NASDAQ:AXGT)
Historical Stock Chart
From Jun 2021 to Jun 2022
